Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients

Transfusion Clinique et Biologique

Volumn 8, Issue 3, 2001, Pages 200-206

  Busch, M P ^a  

^a Blood Centers of the Pacific   (United States)

Author keywords

Blood transfusion; HCV blood donor; Hepatitis C virus; Pathogenesis

Indexed keywords

HEPATITIS C VACCINE;

ANTIBODY SCREENING; BLOOD DONOR; BLOOD TRANSFUSION; CONFERENCE PAPER; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE TRANSMISSION; EPIDEMIOLOGICAL DATA; GENE AMPLIFICATION; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS NON A NON B; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; NONHUMAN; PATHOGENESIS; SEROCONVERSION; VACCINATION; VIREMIA; VIRUS DETECTION; VIRUS DIAGNOSIS; VIRUS LOAD;

EID: 0034912123     PISSN: 12467820     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1246-7820(01)00125-2     Document Type: Conference Paper

References (46)

1. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
2. Hepatitis C: The clinical spectrum of the disease
3. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
4. The natural history of community-acquired hepatitis C in the United States
5. Acute hepatitis C
6. Recovery, persistence, and sequelae in HCV infection: A perspective on long-term outcome
7. Demographic correlates of transfusion transmitted viral infections in US blood donors
8. Trends in incidence and prevalence of major transfusion-transmissible viral infections in United States blood donors, 1991 to 1996
9. Germs, gels, and genomes: A personal recollection of 30 years in blood safety testing
10. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease
11. Risk factors for hepatitis C virus infection in United States blood donors
12. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: Quasispecies nature of HCV genome distribution
13. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies
14. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region
15. Methods for determining the hepatitis C virus genotype
16. Clinical significance of hepatitis C virus genotypes and quasispecies
17. Why is there such difficulty in defining the natural history of hepatitis C?
18. NIH consensus development conference panel statement: Management of hepatitis C
19. Closing the windows on viral transmission by blood transfusion
20. Frequency of hepatitis C virus (HCV) RNA-positive antibody-negative subjects in blood donor and high-risk populations
21. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes
22. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection
23. The natural history of hepatitis C infection: Host, viral and environmental factors
24. Dynamics of HCV viremia during early HCV infection: Implications for minipool (MP vs individual donations (ID) nucleic acid amplification testing (NAT)
25. Detection of HCV by nucleic acid testing in a seronegative donor
26. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis
27. Evaluation of antibodies to hepatitis C virus in a study or transfusion associated hepatitis
28. Dynamics of HCV viremia and seroconversion in transfusion-acquired HCV infections
29. Comparison of preliminary observed yield of HCV and HIV minipool (MP) nucleic acid testing (NAT) with predictions from the incidence/window period (INC/WP) model
30. NAT of the United States and Canadian blood supply
31. Prolonged antibody-negative HCV viremia in a US blood donor with apparent HCV transmission to a recipient
32. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses
33. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: Cytofluorometric assessment of envelope glycoprotein 2 binding to target cells
34. Lack of protective immunity against reinfection with hepatitis C virus
35. Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients
36. Course of infection and evolution of monoclonal hepatitis C virus (HCV) strain H77 in chimpanzees transfected with RNA transcripts from an infectious cDNA clone
37. Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence
38. Interaction between the hepatitis C virus and the immune system
39. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection
40. Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection
41. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C
42. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response
43. Detection of type 2-like T-helper cells in hepatitis C virus infection: Implications for hepatitis C virus chronicity
44. Analysis of a successful immune reponse against hepatitis C virus
45. Natural history of hepatitis C virus infection in multitransfused hemphiliacs: Effect of coinfection with human immunodeficiency virus
46. Hepatitis C virus/human immunodeficiency virus coinfection: Clinical management issues